SCHEMBL20134796

SCHEMBL20134796

Cc1cc(C)c(N2CCN(C(=O)c3ccc([C@@]4(C)NC(=O)NC4=O)cc3)CC2)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
HIF1A Q16665 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CRBN Q96SW2 2/20 0.39
ADAMTS5 Q9UNA0 5/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ADAM17 P78536 2/20 0.37
TSHR P16473 1/20 0.37
GBA1 P04062 3/20 0.37
MAPK1 P28482 1/20 0.37
USP2 O75604 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
MMP2 P08253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688482 1.00 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2LMNAHTTKDM4E
SCHEMBL20134799 1.00 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2LMNAHTTKDM4E
SCHEMBL20135396 0.90 GBA1 (0.38) SMN1; SMN2LMNAHTTKDM4EADAMTS5
SCHEMBL29688802 0.90 GBA1 (0.38) SMN1; SMN2LMNAHTTKDM4EADAMTS5
SCHEMBL20134817 0.86 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2LMNAHTTKDM4E
SCHEMBL20134948 0.86 ADAMTS5 (0.44) ADAMTS5ADAM17MMP2
SCHEMBL20135056 0.86 CRBN (0.43) ALDH1A1SMN1; SMN2HTTCRBNADAMTS5
SCHEMBL20134928 0.86 ADAMTS5 (0.44) ADAMTS5ADAM17MMP2
SCHEMBL20134931 0.86 ADAMTS5 (0.44) ADAMTS5ADAM17MMP2
SCHEMBL29688621 0.86 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2LMNAHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN claimed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US claimed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US claimed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP claimed
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ALDH1A1 584/4885SMN1; SMN2 2532/4885LMNA 4264/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ALDH1A1 610/4885SMN1; SMN2 2476/4885LMNA 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.